Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Case Comprehensive Cancer Center
The study will assess the diagnostic performance of \[F-18\] fluciclovine PET/CT compared to \[F-18\] NaF PET/CT as the reference standard. Each bone lesion identified on \[F-18\] NaF PET/CT will be compared with the level of \[F-18\] fluciclovine uptake
The primary objective is to assess \[F-18\] fluciclovine efficacy in the evaluation of osseous metastatic disease in prostate cancer on a lesion-by-lesion comparison with \[F-18\] NaF as a the reference standard.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Referred for initial staging or restaging of prostate cancers with clinical suspicion of bone metastases.
Must understand and voluntarily sign an Informed Consent Document
You may not be if
Cannot tolerate imaging up to 60 minutes of total imaging
Clareo Health | Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease
